On November 13, Revolution Medicines, Inc. fell 4.14% in Regular Trading, trading at $168.77 per share, with turnover of $30.6172 million.
The clearest catalyst in recent market coverage is continued post-earnings valuation digestion after the company’s third-quarter report, despite results beating expectations and analysts lifting price targets.
Background shows Revolution Medicines, Inc. reported third-quarter EPS of $(1.90), better than the $(2.42) consensus estimate, while revenue was $197.559 million, far above the prior market estimate cited in coverage, though that comparison was flagged as not fully comparable. After the report, RBC raised its target price to $321, JP Morgan lifted its target to $289, and Bank of America maintained a Buy rating with a $274 target, reflecting confidence in Rasonque’s commercialization potential following its approval. Even so, recent coverage indicated that earlier optimism had already been substantially priced in, leaving the shares under near-term valuation pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments